PT-141

99%+ Purity USA Tested

Research Use Only. Not for Human or Veterinary Use

PT-141 (Bremelanotide): Cyclic melanocortin receptor agonist peptide targeting MC3R and MC4R, CAS 189691-06-3, MW 1025.2 g/mol, ≥99% purity. Lyophilized powder for laboratory use.

$69.00

Peptide Name	PT-141 (Bremelanotide)
CAS Number	189691-06-3
Molecular Formula	C₅₀H₆₈N₁₄O₁₀
Molecular Weight	~1025.2 g/mol
Mechanism Class	Melanocortin receptor agonist (MC3R / MC4R)
Appearance	White lyophilized powder
Purity	≥99% (HPLC)
Storage	-20°C, desiccated, protected from light
Solubility	Soluble in sterile water or DMSO

This product is not intended for human or animal use. For scientific research only.

VivePeptides provides detailed analytical results including High-Performance Liquid Chromatography (HPLC) and mass spectrometry data for all peptides. These reports confirm peptide purity, composition, and molecular accuracy, giving researchers full transparency and confidence in the materials used for their studies.

All VivePeptides products undergo independent third-party laboratory testing to verify identity, purity, and consistency. This additional layer of quality control ensures that each peptide meets strict research-grade standards before being made available for laboratory use.

VivePeptides peptides should be stored in a cool, dry environment and protected from light and moisture. Lyophilized peptides are best kept refrigerated or frozen until use to maintain stability. Once reconstituted for research purposes, peptides should be stored according to standard laboratory protocols, typically under refrigeration, and handled using proper aseptic techniques to preserve integrity throughout the study period.

OVERVIEW

What Is PT 141 Peptide?

PT 141 is a synthetic cyclic heptapeptide and melanocortin receptor agonist, also known by its pharmaceutical name Bremelanotide. Originally derived from the melanotropin peptide Melanotan II (MT-II), PT 141 was developed during research into melanocortin receptor signaling and was subsequently found to activate central nervous system pathways associated with sexual function. In 2019, the FDA approved Bremelanotide for a specific indication, making it one of the few melanocortin receptor agonists to achieve regulatory approval for clinical use.

As a research peptide, PT 141 belongs to the class of melanocortin receptor ligands that interact with the MC3R and MC4R receptor subtypes. Unlike compounds that act on peripheral vascular mechanisms, PT 141 research has demonstrated a centrally acting mechanism through hypothalamic and limbic neural pathways. This neurogenic mechanism of action has made PT 141 a valuable tool in neuroscience research, melanocortin receptor pharmacology, and neuroendocrine signaling studies.

Melanocortin Receptor Agonist

Synthetic cyclic heptapeptide targeting MC3R and MC4R receptor subtypes in the central nervous system

≥99% HPLC Purity

Every batch verified via high-performance liquid chromatography

USA Tested & Verified

Third-party analytical testing performed in USA laboratories

RESEARCH

PT 141 Mechanism of Action in Research

The PT 141 mechanism of action is distinguished by its central nervous system activity, operating through melanocortin receptor pathways in the brain rather than peripheral vascular mechanisms. Research over the past two decades has elucidated the specific receptor interactions and downstream signaling cascades that mediate its observed effects.

MC3R and MC4R Receptor Activation

PT 141 functions as a selective agonist for melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors, with preferential activity at MC4R. These receptors are G-protein coupled receptors expressed primarily in the hypothalamus and limbic regions of the brain. Research by Hadley and Dorr (2006) demonstrated that PT 141 binding to MC4R activates Gs-protein signaling, increasing intracellular cAMP and triggering downstream neural cascades. The MC4R receptor has been identified as a key mediator of PT 141’s observed central effects in preclinical models.

Neurotransmitter System Modulation

Research indicates that MC4R activation by PT 141 modulates multiple neurotransmitter systems. Published studies have demonstrated downstream effects on dopaminergic signaling in mesolimbic pathways, norepinephrine release, and oxytocin secretion. Diamond et al. (2006) published findings showing that PT 141 administration in animal models produced measurable changes in hypothalamic neurotransmitter activity, establishing a direct link between melanocortin receptor activation and neurogenic signaling cascades.

Cyclic Peptide Structure and Receptor Selectivity

PT 141’s cyclic lactam bridge structure, formed between the Asp and Lys residues, contributes to its receptor selectivity and metabolic stability. Research into the structure-activity relationships of melanocortin peptides has demonstrated that this cyclization enhances binding affinity for MC3R and MC4R while reducing activity at other melanocortin receptor subtypes. The incorporation of D-Phe (D-phenylalanine) further enhances receptor binding and resistance to enzymatic degradation compared to linear melanocortin peptides.

COMPARISON

PT 141 vs Melanotan II: Research Peptide Comparison

Both PT 141 and Melanotan II (MT-II) are synthetic melanocortin receptor agonists derived from the same parent peptide, alpha-MSH. While they share structural similarities and melanocortin receptor affinity, they differ in their receptor selectivity profiles and primary research applications. Understanding these differences helps researchers select the appropriate compound for their specific laboratory protocols.

Feature	PT 141	Melanotan II
Origin	Derived from Melanotan II	Synthetic analog of alpha-MSH
Amino Acids	7 (cyclic)	7 (cyclic)
CAS Number	189691-06-3	121062-08-6
Molecular Weight	1025.2 Da	1024.2 Da
Primary Research Focus	MC3R/MC4R central nervous system signaling	Broad melanocortin receptor activation
Receptor Selectivity	Preferential MC4R agonism	Non-selective MC1R through MC5R
Key Structural Difference	Acetylated N-terminus, no melanotropic ring	Full melanotropic core with Nle substitution
Research Volume	100+ published studies	80+ published studies

Both peptides are used in melanocortin receptor pharmacology research. PT 141 is preferred for studies investigating central nervous system melanocortin signaling due to its MC4R selectivity. Melanotan II is used more broadly in melanocortin receptor mapping and melanogenesis research due to its non-selective receptor profile. VivePeptides offers both PT 141 and Melanotan II at research-grade purity from our USA-based facility.

RESEARCH STUDIES

PT 141 Research Applications & Published Studies

PT 141 research spans over two decades of published preclinical and clinical literature. The following areas represent the most actively investigated applications. All references are to research contexts only.

Melanocortin Receptor Pharmacology

PT 141 has served as a primary tool for mapping melanocortin receptor function in the central nervous system. Hadley and Dorr (2006) published comprehensive reviews of melanocortin receptor pharmacology using PT 141 as a selective probe. Research by Wikberg et al. (2000) used melanocortin ligands including PT 141 precursors to map receptor distribution and signaling in hypothalamic and limbic brain regions, contributing to the understanding of melanocortin receptor biology.

Neuroendocrine Signaling Research

Published studies have examined PT 141’s effects on neuroendocrine pathways. Diamond et al. (2006) reported observations of PT 141-mediated changes in hypothalamic neurotransmitter levels in preclinical models. Subsequent research explored downstream effects on oxytocin release, dopaminergic activity, and hypothalamic-pituitary axis function, establishing PT 141 as a valuable pharmacological tool for investigating brain-mediated neuroendocrine signaling.

Central Nervous System Receptor Mapping

PT 141 research has contributed to the broader understanding of G-protein coupled receptor signaling in the CNS. Studies investigating PT 141’s interaction with MC3R and MC4R have provided insights into receptor desensitization, internalization, and downstream cAMP/PKA signaling that are applicable beyond melanocortin-specific research. These pharmacological studies have been published in journals including the Journal of Pharmacology and Experimental Therapeutics and Peptides.

QUALITY ASSURANCE

Quality & Testing Standards

VivePeptides maintains rigorous quality control for every batch of PT 141 peptide. Our commitment to research-grade purity ensures that laboratories receive consistent, reliable compounds for their investigations.

HPLC & Mass Spectrometry

Every batch of PT 141 undergoes high-performance liquid chromatography (HPLC) and mass spectrometry analysis to confirm identity, purity, and molecular weight.

Third-Party Verified

All VivePeptides PT 141 is independently verified through third-party analytical laboratories based in the USA. Testing documentation is available for every lot.

≥99% Purity Standard

Our PT 141 consistently meets or exceeds ≥99% purity as determined by HPLC analysis, ensuring research-grade quality for laboratory applications.

FAQ

Frequently Asked Questions About PT 141

What is PT 141 used for in research?

PT 141 is used in research settings to study melanocortin receptor pharmacology, central nervous system signaling, neuroendocrine function, and G-protein coupled receptor biology. It is one of the most selective MC4R agonists available for laboratory research. PT 141 is sold for research use only.

What purity is VivePeptides PT 141?

VivePeptides PT 141 is manufactured to ≥99% purity as verified by HPLC analysis. Every batch is tested and verified through independent third-party USA-based laboratories to ensure consistent research-grade quality.

How should PT 141 be stored?

Lyophilized PT 141 should be stored at -20°C, protected from light and moisture. Once reconstituted, the solution should be stored at 2 to 8°C and used within 14 days for optimal stability. PT 141 is soluble in sterile water or DMSO. Avoid repeated freeze-thaw cycles.

What is the difference between PT 141 and Melanotan II?

PT 141 (Bremelanotide) and Melanotan II are both cyclic melanocortin receptor agonists with similar molecular weights (1025.2 Da vs 1024.2 Da). The primary difference is receptor selectivity: PT 141 has preferential activity at MC3R and MC4R in the central nervous system, while Melanotan II is a non-selective agonist active across MC1R through MC5R. This makes PT 141 the preferred compound for CNS-specific melanocortin research, while MT-II is used more broadly for melanogenesis and receptor mapping studies.

Is VivePeptides PT 141 third-party tested?

Yes. Every lot of VivePeptides PT 141 undergoes independent third-party testing at USA-based analytical laboratories. Testing includes HPLC purity analysis and mass spectrometry identity confirmation. Results are available upon request for qualified researchers.

Related Research Peptides

Explore other research-grade peptides available from VivePeptides. Each product meets the same rigorous purity and testing standards.

Melanotan II

Non-selective melanocortin receptor agonist for melanogenesis and receptor research

BPC-157

Gastric pentadecapeptide for multi-pathway protective research

CJC-1295 + Ipamorelin

Growth hormone secretagogue research blend for neuroendocrine studies

Sermorelin

GHRH analog for pituitary function and GH release research

Explore More Research Peptides

Semaglutide · Tirzepatide · Selank · Semax · Tesamorelin · NAD+ · SNAP-8 · All Peptides →